Revolution Medicines Inc Ordinary Shares RVMD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
-
Revolution Medicines Gets FDA Breakthrough Designation for Cancer Treatment
-
Bloomberg 500 (B500) Index Adds Ten Securities Following September Reconstitution
-
Revolution Medicines' Application for Pancreatic Cancer Treatment Accepted by FDA
-
Revolution Medicines' Pancreatic-Cancer Drug Cleared for Expanded Access
-
Revolution Medicines Shares Slide Premarket After Merck Talks Cool
-
AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition
-
Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment
Trading Information
- Previous Close Price
- $205.89
- Day Range
- $204.07–208.82
- 52-Week Range
- $45.61–224.31
- Bid/Ask
- $205.30 / $207.00
- Shares Outstanding
- 214.34M
- Market Cap
- $44.29B
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 883
- Website
- https://www.revmed.com
Valuation
|
Metric
|
RVMD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 16.92 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RVMD
|
|---|---|
Quick Ratio | 11.12 |
Current Ratio | 11.38 |
Interest Coverage | −30.46 |
Quick Ratio
RVMD
Profitability
|
Metric
|
RVMD
|
|---|---|
Return on Assets (Normalized) | −46.51% |
Return on Equity (Normalized) | −68.83% |
Return on Invested Capital (Normalized) | −62.48% |
Return on Assets
RVMD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|L^LFnxj | LOCK|dlPz | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!VBtdB | LOCK|ypzP> | $76B | |||
| Moderna Inc
MRNA
| LOCK|R&vn&Qp | LOCK|#f> | $75B | |||
| argenx SE ADR
ARGX
| LOCK|%Fmjl$ | LOCK|j$@ | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|gpTx>v | LOCK|&^> | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>Vw!BFs | LOCK|P%rB | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$$%Zt#p | LOCK|c?#BM | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|dSXdr?M | LOCK|zLz | $24B | |||
| Incyte Corp
INCY
| LOCK|R!&S>f | LOCK|%S% | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&?bn@k | LOCK|hy> | $15B |
United States